plasmaCare
Financiado
A small portable cold plasma device for the treatment of chronic and acute woun...
terraplasma GmbH has developed a small, portable and battery-operated device – plasma care – for the treatment of chronic and acute wounds. Besides ensuring a sufficient supply of oxygen, avoiding an infection is the most importan...
terraplasma GmbH has developed a small, portable and battery-operated device – plasma care – for the treatment of chronic and acute wounds. Besides ensuring a sufficient supply of oxygen, avoiding an infection is the most important criterion to enable fast and uncomplicated wound healing. Hard-to-heal wounds have a negative impact on patient wellbeing, are challenging for clinicians to manage and are costly to the health economy. plasmaCare incorporates its innovative cold plasma technology where plasma care will allow for a disruptive wound therapy that can save healthcare costs by facilitating early discharge from hospital, reducing wound dressing frequency (e.g. nursing time) and promote faster healing processes.
terraplasma’s ambition is to reach the European market in 2020 with the innovation project boosting their efforts to fulfil this strategy: results of clinical studies on plasmaCare and their dissemination through the European network of skin specialists will be crucial to gain traction among patients, and healthcare providers in order to achieve the new product acceptance among customers and ultimately, their trust.
Incorporated in Germany in 2011 and maintaining its core business in Europe with an annual balance sheet of ~ €1M and a staff headcount of 9, the company has evolved along the years from a pure R&D start-up into a commercial enterprise. The proposed work in Phase 1 of the SME instrument fits into the overall terraplasma plan to reach market by contributing the financial resources needed to plan a fast, sound and wider deployment of the plasmaCare solution and the market uptake. It will also allow the SME to accomplish key feasibility activities and reduce the business risks, such as business planning, customer identification and outreach, and stronger IP management strategy.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2018-06-20
Fecha Fin: 2018-10-31
Fecha Fin: 2018-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
TERRAPLASMA GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
252.03K€ |
Participante